CN111936124A - 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用 - Google Patents

一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用 Download PDF

Info

Publication number
CN111936124A
CN111936124A CN201980023670.6A CN201980023670A CN111936124A CN 111936124 A CN111936124 A CN 111936124A CN 201980023670 A CN201980023670 A CN 201980023670A CN 111936124 A CN111936124 A CN 111936124A
Authority
CN
China
Prior art keywords
pharmaceutical composition
salt
indacaterol
acid
glycopyrronium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980023670.6A
Other languages
English (en)
Inventor
张春雨
秦践
李麒麟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Haisco Pharmaceutical Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Priority to CN202310107966.4A priority Critical patent/CN116173025A/zh
Publication of CN111936124A publication Critical patent/CN111936124A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

一种不含推进剂的气雾剂药物组合物，其包含格隆铵可药用的盐、茚达特罗可药用的盐和水，所述药物组合物每100mL含格隆铵0.045±0.001g至0.090±0.001g、茚达特罗0.099±0.001g至0.198±0.001g；该药物组合物特别适合于借助于雾化器而将活性物质形成气雾以在气喘及COPD症状中以吸入方式施用活性剂。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201980023670.6A 2018-07-26 2019-07-03 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用 Pending CN111936124A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310107966.4A CN116173025A (zh) 2018-07-26 2019-07-03 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018108204503 2018-07-26
CN201810820450 2018-07-26
PCT/CN2019/094486 WO2020019952A1 (zh) 2018-07-26 2019-07-03 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310107966.4A Division CN116173025A (zh) 2018-07-26 2019-07-03 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用

Publications (1)

Publication Number Publication Date
CN111936124A true CN111936124A (zh) 2020-11-13

Family

ID=69182038

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310107966.4A Pending CN116173025A (zh) 2018-07-26 2019-07-03 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
CN201980023670.6A Pending CN111936124A (zh) 2018-07-26 2019-07-03 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310107966.4A Pending CN116173025A (zh) 2018-07-26 2019-07-03 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用

Country Status (3)

Country Link
CN (2) CN116173025A (zh)
TW (1) TWI758617B (zh)
WO (1) WO2020019952A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021068961A1 (zh) * 2019-10-11 2021-04-15 四川海思科制药有限公司 一种吸入溶液药物组合物及其制备方法
US20210220367A1 (en) * 2020-01-20 2021-07-22 Cai Gu Huang Inhalable formulation of a solution containing glycopyrrolate and olodaterol hydrochloride
CN111349036B (zh) * 2020-03-13 2022-03-08 安徽恒星制药有限公司 一种格隆溴铵的替代物及其制备方法和医药用途
US20210386730A1 (en) * 2020-06-09 2021-12-16 Cai Gu Huang Pharmaceutical formulation containing glycopyrrolate and indacaterol maleate
CA3179014A1 (en) 2020-09-29 2022-04-07 iPharma Labs, Inc. Liquid formulations of indacaterol
WO2023192445A1 (en) * 2022-03-30 2023-10-05 Aerorx Therapeutics Llc Liquid formulations of indacaterol and glycopyrronium

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1333682A (zh) * 1998-10-17 2002-01-30 贝林格尔英格海姆法玛公司 可储存的含福莫特罗的活性物质浓缩液
KR20030065509A (ko) * 2000-11-13 2003-08-06 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 티오트로퓸 염 및 살메테롤 염에 기초한 신규한 의약 조성물
CN1473044A (zh) * 2000-10-31 2004-02-04 ���ָ��Ӣ��ķ�������Ϲ�˾ 含提欧川平盐的溶液的可吸入制剂
CN103785086A (zh) * 2012-10-26 2014-05-14 阿克蒂维罗有限责任公司 用于喷雾疗法的吸入设备
WO2017192767A1 (en) * 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Droplet delivery device for delivery of fluids to the pulmonary system and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
TW201607944A (zh) * 2013-12-05 2016-03-01 吉斯藥品公司 雜芳基衍生物
CN105982880A (zh) * 2015-03-16 2016-10-05 四川海思科制药有限公司 一种干粉吸入剂药物组合物及其制备方法
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1333682A (zh) * 1998-10-17 2002-01-30 贝林格尔英格海姆法玛公司 可储存的含福莫特罗的活性物质浓缩液
CN1473044A (zh) * 2000-10-31 2004-02-04 ���ָ��Ӣ��ķ�������Ϲ�˾ 含提欧川平盐的溶液的可吸入制剂
KR20030065509A (ko) * 2000-11-13 2003-08-06 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 티오트로퓸 염 및 살메테롤 염에 기초한 신규한 의약 조성물
CN103785086A (zh) * 2012-10-26 2014-05-14 阿克蒂维罗有限责任公司 用于喷雾疗法的吸入设备
WO2017192767A1 (en) * 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Droplet delivery device for delivery of fluids to the pulmonary system and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
罗泽如 等: "COPD患者使用噻托溴铵吸乐装置转换为能倍乐装置的效果研究", 《岭南急诊医学杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法

Also Published As

Publication number Publication date
TWI758617B (zh) 2022-03-21
WO2020019952A1 (zh) 2020-01-30
CN116173025A (zh) 2023-05-30
TW202012369A (zh) 2020-04-01

Similar Documents

Publication Publication Date Title
TWI758617B (zh) 包含格隆銨鹽及茚達特羅鹽的氣霧劑藥物組合物、其製備方法與用途
US7611694B2 (en) Aerosol formulation for inhalation comprising an anticholinergic
JP4537652B2 (ja) 抗コリン作用薬及びシクレソニドをベースとする新規薬剤組成物
US20040176338A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
US20060205758A1 (en) Method for reducing the mortality rate
JP4602767B2 (ja) 抗コリン作用薬を含有する吸入用エアロゾル製剤
US20090075990A1 (en) Aerosol Formulation for Inhalation Containing an Anticholinergic Agent
US20090170839A1 (en) Aerosol formulation for inhalation containing an anticholinergic agent
US20090306065A1 (en) Aerosol formulation for inhalation containing an anticholinergic agent
US20090317337A1 (en) Aerosol formulation for inhalation containing an anticholinergic agent
US20040192675A1 (en) Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20090221626A1 (en) Aerosol formulation for inhalation containing an anticholinergic agent
CA2575385A1 (en) Aerosol formulation for inhalation, containing an anticholinergenic agent
MXPA03004164A (es) Nuevas composiciones de medicamentos a base de sales de tiotropio y sales del salmeterol.
JP2007523119A (ja) ベンジル酸エステル及び可溶性ｔｎｆ受容体融合タンパク質を基にした新規な医薬組成物
JP6503043B2 (ja) 新規噴射剤含有チオトロピウム製剤
JP2006500400A (ja) 肺のリハビリ計画に肺疾患に罹った患者を参加させ、該計画から成果を得るために該患者の能力を向上させるための方法
CN111971034A (zh) 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用
JP2008500278A (ja) フルオレンカルボン酸エステル及び可溶性ｔｎｆ受容体融合タンパク質を基にした新規な医薬組成物
JP2004512379A (ja) 新規医薬組成物
US20060251656A1 (en) New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies
US20070021333A1 (en) Pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins
US20050187157A1 (en) Pharmaceutical compositions based on anticholinergics and pegsunercept
CA2515534A1 (en) New pharmaceutical compositions based on anticholinergics and tace-inhibitors
CA2553369A1 (en) Pharmaceutical compositions based on anticholinergics and pegsunercept

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20201113